Chugai and Taisho to Co-Develop and Market Antiresorptive Bisphosphonate R484.
Under the agreement, Chugai will receive an upfront fee and milestone payments from Taisho.
R484 is currently in phase II clinical trials in Japan and is expected to be the next generation osteoporosis treatment drug. It is marketed under the brand name Bonviva in the U.S.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Sep 13, 2006|
|Previous Article:||Dainippon to Launch IC Shelf System.|
|Next Article:||Toppan to Release IC Circulation Management System.|